NIH-FDA Tobacco Control Regulatory Science

Administrative and Budgetary Requirements

Pre-Application Webinar
July 15, 2019
11am-1pm

R21 Awards in Tobacco Control
Regulatory Research

Amy Bucheimer
Grants Management Specialist
Grants Management Branch
National Institute on Drug Abuse
R21 Awards in Tobacco Control Regulatory Research

RFA funding levels:

• The NIH, via support from the FDA Center for Tobacco products (CTP), intends to fund:

  • RFA-OD-19-021: up to 7 R21s, corresponding to a total of up to $1.5 million, for fiscal year 2020. Future year amounts will depend on availability of funds.

  • RFA-OD-19-022: up to 5 R21s, corresponding to a total of $1 million for fiscal year 2020. Future year amounts will depend on availability of funds.
R21 Awards in Tobacco Control Regulatory Research

• RFAs published, as of July 8, 2019:

  • RFA-OD-19-021, Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed)

  • RFA-OD-19-022, Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed)
Important dates to remember for RFA-OD-19-021, “Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed)”

Letter of intent (LOI) due dates:
• 60 days prior to the application due date. Please note, although LOIs are typically due 30 days before the due date, for this FOA LOIs are due 60 days prior to the application date.

Application due dates:
• October 8, 2019, August 7, 2020, March 8, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• No late applications will be accepted for this Funding Opportunity Announcement.
• Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Earliest start dates:
• July 2020, April 2021, September 2021
Important dates to remember for RFA-OD-19-022, “Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed)”

Letter of intent (LOI) due dates:
• 60 days prior to the application due date. Please note, although LOIs are typically due 30 days before the due date, for this FOA LOIs are due 60 days prior to the application date.

Application due dates:
• October 8, 2019, August 7, 2020, March 8, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

• No late applications will be accepted for this Funding Opportunity Announcement.

• Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Earliest start dates:
• July 2020, April 2021, September 2021
R21 Awards in Tobacco Control Regulatory Research

Project periods for each R21 grant opportunity:

• **RFA-OD-19-021**, Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed): *The maximum project period is 2 years.*

• **RFA-OD-19-022**, Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed): *The maximum project period is 2 years.*
Post-Award Information for any award, funded via FDA:

- Mid-period progress reporting due every 6 months, following the project/budget start dates.
  - Mid-period progress reporting is also required during no-cost extensions.

- All FDA-funded awards are excluded from carryover authority; therefore, prior approval is required (see terms on award notice)
Administrative QUESTIONS and/or CONCERNS?

Contact information:

Amy Bucheimer
301-827-6694
bucheimera@mail.nih.gov